Form 4 for SYRE Spyre Therapeutics, Inc.

Accepted 2022-03-15 00:00:00 ET · period of report 2022-03-11 · accession 0001209191-22-018942 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2022-03-15	2022-03-11+	SYRE	Quinn Anthony G.	Pres, CEO, Dir	P - Purchase	$1.94	+144.7K	473.5K	+44%	+$280.8K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-03-11	P	A	34,777	$2.06	363,572	D	—	—	(F1) The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.995 to $2.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
2	Common	Common Stock	2022-03-14	P	A	67,472	$1.93	431,044	D	—	—	(F2) The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.80 to $1.93 per share, inclusive.
3	Common	Common Stock	2022-03-15	P	A	42,417	$1.86	473,461	D	—	—	(F3) The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.89 to $2.00 per share, inclusive.